Abstract
F. d’Amore1, P. Gaulard2, L. Trumper3, P. Corradini4, W.-S. Kim5, L. Specht6, M. Bjerregaard Pedersen1 & M. Ladetto7, on behalf of the ESMO Guidelines Committee* Department of Hematology, Aarhus University Hospital, Aarhus, Denmark; Department of Pathology, Hopital Henri Mondor, Creteil, France; Department of Hematology and Oncology, Georg August University, Gottingen, Germany; Department of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milan, Milan, Italy; Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Seoul, Korea; Department of Oncology and Hematology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Divisione di Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
